SAN FRANCISCO — Nearly half of patients with noninfectious uveitis treated with suprachoroidal CLS-TA gained three or more lines of visual acuity after 24 weeks, according to a presentation at the American Academy of Ophthalmology annual meeting.
Steven Yeh, MD, M. Louise Simpson Associate Professor of Ophthalmology at Emory Eye Center, and colleagues conducted the PEACHTREE study – a phase 3, randomized, controlled, double masked, multicenter trial – to assess the effect of suprachoroidal CLS-TA (triamcinolone acetonide injectable suspension) on IOP among patients with noninfectious uveitis compared with sham.
“The suprachoroidal delivery concept takes advantage of the fact that you get high levels of drug within in the retina, the retinal pigment epithelium and the choroid with potentially fewer side effects including IOP and cataract, which we are all concerned about,” Yeh said during his presentation.
The researchers randomly assigned 160 patients 3:2 to receive suprachoroidal CLS-TA or sham at baseline and week 12. Rescue therapy was administered if needed. They evaluated preinjection IOP every 4 weeks through week 24.
The primary endpoint was the percentage of patients gaining three or more lines of vision acuity at week 24. Other endpoints included an increase of 10 mmHg or more in IOP from baseline, an IOP of more than 30 mmHg at any visit, medication use for IOP and surgery for IOP.
Results showed that 47% of patients who received suprachoroidal CLS-TA gained three or more lines of visual acuity, compared with only 16% of patients receiving sham.
The percentage of patients receiving CLS-TA and sham who had a 10 mmHg increase in IOP from baseline was similar (15.8% vs. 17.2%; P > .05). The percentage of patients who had an IOP of more than 30 mmHg at any visit was also similar between the CLS-TA and sham groups (5.3% vs. 7.8%; P >.05). Additionally, a comparable percentage of patients in both treatment arms received IOP-lowering medication (7.3% vs. 9.4%; P > .05). Surgical intervention for IOP elevation was not necessary in any patients.
There were no serious adverse events linked to CLS-TA.
“The CLS-TA group actually did better than sham for all anatomic locations from week 4 on to week 24,” Yeh said. – by Alaina Tedesco
Reference: Yeh S. Suprachoroidal CLS-TA and IOP: Results from the phase 3 PEACHTREE clinical trial for uveitis. Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.
Disclosure: Yeh reports being a consultant for Clearside and Santen Inc.